Skip to content
10-Q

Quarterly Report

MoonLake Immunotherapeutics MLTX

0001821586-25-000011

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt Q1 2025 · Mar 31, 2025 $73.02M
Long Term Debt Q1 2025 · Dec 31, 2024 $0
Cash And Equivalents Q1 2025 · Mar 31, 2025 $271.57M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $180.43M
Stockholders Equity Q1 2025 · Mar 31, 2025 $407.52M
Stockholders Equity Q1 2025 · Dec 31, 2024 $446.83M
Current Liabilities Q1 2025 · Mar 31, 2025 $23.98M
Current Liabilities Q1 2025 · Dec 31, 2024 $22.46M
Total Liabilities Q1 2025 · Mar 31, 2025 $98.68M
Total Liabilities Q1 2025 · Dec 31, 2024 $24.54M
Current Assets Q1 2025 · Mar 31, 2025 $506.26M
Current Assets Q1 2025 · Dec 31, 2024 $474.29M
Total Assets Q1 2025 · Mar 31, 2025 $511.26M
Total Assets Q1 2025 · Dec 31, 2024 $477.93M
Shares Diluted Q1 2025 · Mar 31, 2024 62.64M sh
Capex restated Q1 2025 · Mar 31, 2024 $212K
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$14.95M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.22
Eps Basic Q1 2025 · Mar 31, 2024 −$0.22
Sga Expense restated Q1 2025 · Mar 31, 2024 $6.81M
Rd Expense restated Q1 2025 · Mar 31, 2024 $13.01M
Net Income restated Q1 2025 · Mar 31, 2024 −$13.67M
Operating Income restated Q1 2025 · Mar 31, 2024 −$19.82M